Upgrade to SI Premium - Free Trial

TD Cowen: 'Neurocrine Bio. (NBIX) Growth Story Appears Intact'

October 14, 2026 9:19 AM
TD Cowen analyst Phil Nadeau reiterated a Buy rating and $220.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments